Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 4 2Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 66Breast Neoplasms 64Prostatic Neoplasms 46Carcinoma, Non-Small-Cell Lung 40Neoplasm Metastasis 23Colorectal Neoplasms 21Multiple Myeloma 20Pain 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Anemia 16Keratosis, Actinic 15Lung Neoplasms 14Cancer Pain 14Lymphoma, Non-Hodgkin 12Lymphoma, Follicular 11Leukemia 11Leukemia, Lymphocytic, Chronic, B-Cell 10Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 9Carcinoma 9Neuroendocrine Tumors 8Melanoma 8Lymphoma 8Ovarian Neoplasms 7Leukemia, Myeloid, Acute 7Uterine Cervical Neoplasms 6Recurrence 6Gastrointestinal Stromal Tumors 6Stomatitis 5Stomach Neoplasms 5

Interventions

Ultracet 1Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × Breakthrough Pain × Clear all
NCT00842829 2012-10-01

Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 4 Terminated
330 enrolled 32 charts

Cancer Pain, Breakthrough Pain

NCT00576173 2010-04-28

An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients

Johnson & Johnson Taiwan Ltd

Phase 4 Completed
60 enrolled

Cancer Pain, Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡